Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

Abstract Background Limited treatment options exist for relapsed advanced lung squamous cell carcinoma (SCC), leading to poor outcomes compared with adenocarcinoma. This study aimed to investigate the efficacy of second-line afatinib versus chemotherapy in patients with advanced lung SCC who progres...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	You-Yi Chen, Shih-Chieh Chang, Cheng-Yu Chang, Chun-Fu Chang, Yi-Chun Lai, Yu-Feng Wei, Chung-Yu Chen
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Afatinib Lung squamous cell carcinoma Second-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/8d57a7a736934ee896d5584c91819337
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d57a7a736934ee896d5584c91819337
record_format	dspace
spelling	oai:doaj.org-article:8d57a7a736934ee896d5584c918193372021-11-21T12:30:09ZReal-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients10.1186/s12885-021-08920-31471-2407https://doaj.org/article/8d57a7a736934ee896d5584c918193372021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08920-3https://doaj.org/toc/1471-2407Abstract Background Limited treatment options exist for relapsed advanced lung squamous cell carcinoma (SCC), leading to poor outcomes compared with adenocarcinoma. This study aimed to investigate the efficacy of second-line afatinib versus chemotherapy in patients with advanced lung SCC who progressed after first-line chemotherapy. Methods In this retrospective, multisite cohort study, we recruited patients with initial locally advanced or metastatic lung SCC from four institutes in Taiwan between June 2014 and October 2020. The primary endpoint of this study was progression-free survival (PFS), and the secondary endpoints were the objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Results The present study enrolled 108 patients: 19 received second-line afatinib, and 89 received second-line chemotherapy. The median ages were 71 and 67 years, respectively. PFS was significantly longer among patients who received afatinib than among those who received chemotherapy (median 4.7 months [95% confidence interval (CI), 0.1–7.5] vs. 2.6 months [95% CI, 0.9–6.7]; hazard ratio (HR) 0.53 [95% CI 0.32–0.88], p = 0.013). Compared with the chemotherapy group, OS was longer in the afatinib group but did not reach significance (median 16.0 months [95% CI, 6.1–22.0] vs. 12.3 months [6.2–33.9]; HR 0.65 [95% CI 0.38–1.11], p = 0.112). Conclusions Afatinib offered a longer PFS and comparable OS to chemotherapy in advanced lung SCC patients in a real-world setting, it may be considered as a 2nd line alternative treatment choice for immunotherapy unfit advanced lung SCC patients.You-Yi ChenShih-Chieh ChangCheng-Yu ChangChun-Fu ChangYi-Chun LaiYu-Feng WeiChung-Yu ChenBMCarticleAfatinibLung squamous cell carcinomaSecond-line treatmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Afatinib Lung squamous cell carcinoma Second-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Afatinib Lung squamous cell carcinoma Second-line treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 You-Yi Chen Shih-Chieh Chang Cheng-Yu Chang Chun-Fu Chang Yi-Chun Lai Yu-Feng Wei Chung-Yu Chen Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
description	Abstract Background Limited treatment options exist for relapsed advanced lung squamous cell carcinoma (SCC), leading to poor outcomes compared with adenocarcinoma. This study aimed to investigate the efficacy of second-line afatinib versus chemotherapy in patients with advanced lung SCC who progressed after first-line chemotherapy. Methods In this retrospective, multisite cohort study, we recruited patients with initial locally advanced or metastatic lung SCC from four institutes in Taiwan between June 2014 and October 2020. The primary endpoint of this study was progression-free survival (PFS), and the secondary endpoints were the objective response rate (ORR), disease control rate (DCR), and overall survival (OS). Results The present study enrolled 108 patients: 19 received second-line afatinib, and 89 received second-line chemotherapy. The median ages were 71 and 67 years, respectively. PFS was significantly longer among patients who received afatinib than among those who received chemotherapy (median 4.7 months [95% confidence interval (CI), 0.1–7.5] vs. 2.6 months [95% CI, 0.9–6.7]; hazard ratio (HR) 0.53 [95% CI 0.32–0.88], p = 0.013). Compared with the chemotherapy group, OS was longer in the afatinib group but did not reach significance (median 16.0 months [95% CI, 6.1–22.0] vs. 12.3 months [6.2–33.9]; HR 0.65 [95% CI 0.38–1.11], p = 0.112). Conclusions Afatinib offered a longer PFS and comparable OS to chemotherapy in advanced lung SCC patients in a real-world setting, it may be considered as a 2nd line alternative treatment choice for immunotherapy unfit advanced lung SCC patients.
format	article
author	You-Yi Chen Shih-Chieh Chang Cheng-Yu Chang Chun-Fu Chang Yi-Chun Lai Yu-Feng Wei Chung-Yu Chen
author_facet	You-Yi Chen Shih-Chieh Chang Cheng-Yu Chang Chun-Fu Chang Yi-Chun Lai Yu-Feng Wei Chung-Yu Chen
author_sort	You-Yi Chen
title	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
title_short	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
title_full	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
title_fullStr	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
title_full_unstemmed	Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
title_sort	real-world effectiveness of second-line afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
publisher	BMC
publishDate	2021
url	https://doaj.org/article/8d57a7a736934ee896d5584c91819337
work_keys_str_mv	AT youyichen realworldeffectivenessofsecondlineafatinibversuschemotherapyforthetreatmentofadvancedlungsquamouscellcarcinomainimmunotherapynaivepatients AT shihchiehchang realworldeffectivenessofsecondlineafatinibversuschemotherapyforthetreatmentofadvancedlungsquamouscellcarcinomainimmunotherapynaivepatients AT chengyuchang realworldeffectivenessofsecondlineafatinibversuschemotherapyforthetreatmentofadvancedlungsquamouscellcarcinomainimmunotherapynaivepatients AT chunfuchang realworldeffectivenessofsecondlineafatinibversuschemotherapyforthetreatmentofadvancedlungsquamouscellcarcinomainimmunotherapynaivepatients AT yichunlai realworldeffectivenessofsecondlineafatinibversuschemotherapyforthetreatmentofadvancedlungsquamouscellcarcinomainimmunotherapynaivepatients AT yufengwei realworldeffectivenessofsecondlineafatinibversuschemotherapyforthetreatmentofadvancedlungsquamouscellcarcinomainimmunotherapynaivepatients AT chungyuchen realworldeffectivenessofsecondlineafatinibversuschemotherapyforthetreatmentofadvancedlungsquamouscellcarcinomainimmunotherapynaivepatients
_version_	1718418957167230976

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

Ejemplares similares